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INTRODUCTION
Glaucoma is a chronic multifactorial progressive optic neuropathy
requiring long-term treatment with topical hypotensive medications(1).
Many classes of drugs are currently available to treat glaucoma, including
cholinergic agents, beta-blockers, alpha adrenergic agonists, carbonic
anhydrase inhibitors, and more recently prostaglandin (PG) analogues(2).
PG analogues increase uveoscleral outflow and may reduce intraocular
pressure up to 40% of its initial value. Systemic side effects induced by
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Purpose: To compare histological changes induced by antiglaucoma
medications in the rabbit conjunctiva. Methods: Fifty New Zealand
rabbits were divided in 5 groups of 10 animals. The left eyes were treated
daily with one drop of bimatoprost 0.03%, travoprost 0.004%, latanoprost
0.005%, timolol maleate 0.5% or artificial tears containing benzalkonium
chloride (BAK) for 30 days. The right eyes served as controls. Superior
limbic conjunctival biopsies were performed at the 8th and 30th day in 5
rabbits of each group. The conjunctiva was fixed with 10% formaldehyde,
followed by HE and PAS staining. Morphohistometric quantitative
analyses were performed to evaluate the following parameters: inflam-
matory infiltrate, epithelial thickness, number of goblet cells, diameter
and number of blood vessels. Results: At the 8th and 30th posttreatment
days, all groups, except one that received artificial tears, exhibited a
diffuse inflammatory infiltrate, composed by lymphocytes and neutro-
phils, which was denser in the timolol group than in the prostaglandin
(PG) analogues groups. At the 30th day, the timolol group also showed an
increased subepithelial collagen density and a significant increase in
epithelial thickness (p=0.0035). The goblet cell density was significantly
increased at the 8th day in the group treated with travoprost (p=0.0006),
and at the 30th day in those treated with bimatoprost (p=0.0021) and
latanoprost (p=0.009). Conclusions: Although a moderate, diffuse in-
flammatory infiltrate was observed in PG-treated eyes, no changes in
conjunctival epithelial thickness or subconjunctival collagen density
were observed with these medications, suggesting that these drugs induce
fewer changes than timolol maleate in the rabbit conjunctiva.
ABSTRACT
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topical PG analogues are rare. On the other hand, iris hyper-
pigmentation, excessive eyelash growth and conjunctival hy-
peremia are reported as local side effects caused by these
drugs(3-6). Moreover, conditions that suggest stimulation or
reactivation of the ocular inflammatory response, such as an-
terior uveitis and cystoid macular edema, were also associated
with the use of PG analogues(7-12).
In patients treated with topical medication, the conjunc-
tiva acts like a semi-permeable membrane that, along with the
cornea, allows absorption of ocular hypotensive drugs. On the
other hand, the conjunctiva responds to chronic treatment
with antiglaucoma drugs with inflammation, scar formation,
keratinization and neovascularization, which may directly
affect its architecture and function(13). Recently, several stu-
dies have evaluated the conjunctival changes induced by
latanoprost(14-16), but there is insufficient information about
the consequences of the use of other PG analogues, such as
travoprost and bimatoprost.
Previous studies with patients who received prolonged
topical medication showed that both hypotensive drugs and its
preservatives (benzalkonium chloride - BAK) may increase the
number of inflammatory cells and fibroblasts in the substantia
propria of the conjunctiva and reduce the number of goblet
cells, inducing ocular surface modifications expressed as dry
eye(13,17-18). The length of administration, concentration and
amount of medication were related to severity of side effects(17-18).
Furthermore, there is strong evidence suggesting that these
changes may increase the risk of failure of trabeculectomy(13,18-21).
However, most pieces of information on this topic were
published before the introduction of PG analogues.
The purpose of this study was to compare histomorpho-
metric changes induced by latanoprost, travoprost and bima-
toprost with those induced by timolol maleate and BAK in
rabbit conjunctiva.
METHODS
Fifty female New Zealand rabbits with similar age and
weight were selected and divided into 5 groups of 10 animals.
The rabbits were treated with bimatoprost 0.03% (LumiganTM,
Allergan, Irvine-CA, USA) (n=10), travoprost 0.004% (Trava-
tanTM,  Forth Worth, TX, USA) (n=10), latanoprost 0.005%
(XalatanTM, Pfizer, New York, USA) (n=10), timolol maleate
0.5% (Timoptic-XETM, Merck, Sharp & Dome, New Jersey,
USA) (n=10) or artificial tears (hypromellose and dextran 70)
(Lacribell™   , Latinofarma, São Paulo, Brazil) (n=10). The drop
volume was 27.05 µl for bimatoprost, 24.26 µl for travoprost,
23.81 µl for latanoprost, 27.9 µl for timolol maleate and
28.3µl for artificial tears. One daily drop of the selected subs-
tance was instilled onto the left cornea of each animal at 8:00
AM for 30 days, while the right eye served as a control. BAK
was the preservative in all tested eye drops at the following
concentrations: bimatoprost (BAK 0.005%), travoprost (BAK
0.015%), latanoprost (BAK 0.02%), timolol maleate (BAK
0.01%), and artificial tears (BAK 0.006%). Limbic superior
conjunctival biopsies (5 mm x 5 mm) were performed at the
8th and 30th days in 5 rabbits of each group, except for the
BAK group, where biopsies were performed only at the 30th
day. After conjunctival biopsies were performed at the 8th
day, these animals were excluded from the study, and the
remaining animals underwent biopsies at the 30th day. A
conscious attempt to perform the conjunctival biopsy con-
sistently at the same peri-limbic location was made. All
samples were taken at the same time of the day (4:00 - 5:00
PM), maintaining the same interval between time of instilla-
tion and time of biopsy for all groups.
The conjunctiva was immediately fixed with 10% for-
maldehyde for 24 hours, followed by routine paraffin em-
bedding and staining with HE (hematoxylin-eosin) and PAS
(periodic acid-Schiff). During the embedding procedure, an
effort was made to ensure that the histological samples were
placed with the epithelium facing the bottom of the histolo-
gical cassette in order to avoid cuts that were not tangential
to the plane of the tissue.
Morphohistometric quantitative analyses were perfor-
med with the software Image Pro-Plus version 4 (IP4) (Media
Cybernetics, Silver Spring, MD). Digital images were acqui-
red under 400x magnification and stored using the same
software. Subsequently, two segments of 200 µm of length
and with 5 µm of thickness of epithelial tissue were ran-
domly selected from each examined field of all slides. These
same-sized linear segments allowed measurement of the fol-
lowing parameters: number and diameter of blood vessels,
number of goblet cells and conjunctival epithelium thick-
ness. Diameter and thickness were measured using default
pre-programmed virtual tools for tissues. Number of blood
vessels and goblet cells were manually counted using a 200-µm
virtual ruler.
Optical qualitative microscopy evaluation was made in
linear conjunctival segments of 200 µm using a virtual ruler
on digital images. The intensity of inflammatory infiltrate
was analyzed qualitatively (absent, mild, moderate or seve-
re) in all biopsy samples comparing pictures taken from 200
and 400x fields of each slide. The histologist (FMF) respon-
sible for measuring all parameters was masked to the medi-
cation group of the rabbit. Repeat masked measurements
performed by the same examiner (FMF) resulted in low coef-
ficients of variability.
One-way ANOVA with a significance level of 5% was used
to compare continuous variables. If any statistically sig-
nificant difference was found, the data were further analyzed
using post hoc comparisons with Fisher’s test (for com-
parisons of up to three groups) or Tukey-Kramer test (com-
parisons of more than 3 groups). Differences were deemed
statistically significant when p values were lower than 0.05.
The experimental procedures used in the investigation
followed the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Reasearch, and the study was appro-
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ved by the Committee Review Boards of the Universidade de
São Paulo and the Hospital Universitário Evangélico de Cu-
ritiba (CAPPESQ nº 161/05).
RESULTS
A significant increase in goblet cells was detected at the
8th day in the travoprost group (p=0.0006). After 30 days of
treatment, there was a significant increase in the number of
goblet cells in the bimatoprost (p=0.0021) and latanoprost
(p=0.009) groups. There were no significant changes in the
number of goblet cells in the timolol and BAK groups
(p>0.05) (Table 1) (Figures 1 and 2).
There was a significant increase in epithelial thickness
(p=0.0035) at the 30th day in the group treated with timolol
maleate (Table 1). Figure 3 illustrates the increased conjunc-
tival epithelial thickness observed in this group, along with a
higher number of epithelial layers. A statistically significant
rise in the mean number of blood vessels was observed at the
30th day in the latanoprost (p=0.0205) and timolol groups
(p=0.0012) (Table 1). There was an overall trend, though not
statistically significant, toward reduced vascular diameter in
the travoprost group at the 8th day (p=0.0758), which became
statistically significant at the 30th day (p=0.0348) (Table 1).
No significant differences were observed between the BAK
and control groups regarding epithelial thicknesses and
number of blood vessels.
There were no significant differences between drop volu-
me of all medications (mean of 25.668 µl, standard deviation
of 2.051 µl and standard error of 0.837 µl).
In the control group and in the group treated with artificial
Table 1. Results of all treated groups comparing to controls at day 8th and 30th
G1 (Bimatoprost) G2 (Travoprost) G3 (Latanoprost)
OD OE p value OD OE p value OD OE p value
M ± SD M ± SD M ± SD M ± SD M ± SD M ± SD
Goblet Cells (n)
8th day 8.80 2.70 11.00 3.68 0.145 5.40 2.37 10.40 2.95 0.001 8.00 2.00 8.40 2.88 0.732
30th day 7.50 1.65 10.30 1.82 0,002 8.40 3.10 7.66 2.73 0.594 7.20 1.54 9.70 2.21 0.009
Epithelial
thickness
8th day 15.23 3.84 11.29 4.37 0.151 13.00 2.83 11.21 2.97 0.552 8.74 0.34 12.83 3.35 0.201
30th day 13.06 4.18 12.81 3.96 0.945 15.42 3.77 13.49 4.24 0.588 10.70 2.51 14.12 4.00 0.371
Vessels (n)
8th day 1.40 1.67 2.40 2.41 0.468 1.20 1.79 1.60 0.55 0.645 1.50 0.58 1.60 1.34 0.894
30th day 1.20 0.84 3.80 3.35 0.130 0.80 1.30 1.80 1.30 0.260 1.00 1.00 4.80 2.78 0.021
Vessels
(diameter)
8th day 15.05 8.14 17.29 7.17 0.658 10.95 9.08 19.73 4.65 0.076 18.09 2.43 4.54 6.45 0.288
30th day 13.89 6.85 17.66 5.15 0.324 23.97 8.15 13.72 2.61 0.035 13.88 1.92    19.15 9.01 0.275
(Cont.) Table 1. Results of all treated groups comparing to controls at day 8th and 30th
G4 (Timolol) G5 (BAK)
OD OE p value OD OE p value
M ± SD M ± SD M ± SD M ± SD
Goblet Cells (n)
8th day 10.40 3.50 9.20 2.30 0.377 na na na na
30th day 9.40 4.20 10.20 2.57 0.617 8.43 3.31 6.71 2.55 0.204
Epithelial
thickness
8th day 14.03 0.36 15.02 4.34 0.773 na na na na
30th day 10.88 0.40 14.19 0.68 0.004 15.57 5.02 16.33 4.10 0.519
Vessels (n)
8th day 1.60 1.52 2.80 1.48 0.242 na na na na
30th day 1.20 0.84 3.80 0.84 0.001 4.20 1.75 4.00 1.51 0.801
Vessels
(diameter)
8th day 14.87 3.76 16.80 3.40 0.345 na na na na
30th day 23.74 6.96 22.62 5.90 0.747 3.80 5.08 14.34 4.47 0.652
na= not available
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A B
Figure 3 - Photomicrographs (400x) of conjunctival samples, HE staining: A) from the control eye (OD) of the timolol-treated group; B) from the
timolol-treated eye (OS). Note marked infiltration with neutrophils on (B). Other changes caused by this drug are visible, such as increased
 epithelial thickness, congested vessels and a discrete change in the immediate subepithelial collagen architecture.
Figure 2 - Photomicrographs (400x) of conjunctival samples, PAS staining. A) from the control eye (OD) of the bimatoprost group; B) from bimatoprost
 treated eye (OS) after 30 days of treatment. Note the increase in number of goblet cells on (B).
A B
Figure 1 - Photomicrographs (400x) of conjunctival samples, PAS staining: A) from the control eye (OD) of the travoprost group; B) from travoprost
 treated eye (OS) after 8 days of treatment. Note the marked increase in number of goblet cells on (B).
A B
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tears, the inflammatory infiltrate was focal, of mild intensity,
with a preponderance of lymphocytes and rare neutrophils.
The eyes treated with antiglaucoma medications, in addition
to the same focal inflammatory pattern found in controls, pre-
sented a more diffuse inflammatory reaction,  consisting of a
mixed population of neutrophils and lymphocytes. This pat-
tern was observed in a moderate intensity in the groups that
used PG analogues and in severe intensity in the timolol
group, which also showed an increase in subepithelial col-
lagen density (Figure 3). There were no significant differences
between the samples obtained at the 8th and 30th post-treatment
days regarding intensity of the inflammatory reaction.
DISCUSSION
Strong evidence provided by clinical and experimental
studies indicates that the chronic use of antiglaucomatous
drugs may induce ocular surface changes, causing discomfort
at instillation, conjunctival inflammation, tear film instabili-
ty, subconjunctival fibrosis, apoptosis of conjunctival epi-
thelium cells and corneal surface alterations(15,18,22-26).
Moreover, these surface changes may increase the risk of
failure when patients undergo glaucoma filtering surgery(27-28).
Broadway et al.(18) observed that patients using different
drops (beta-blocker, miotic + beta-blocker, or miotic + beta-
blocker + sympathomimetic) for more than three years sho-
wed conjunctival changes, including an increased number of
fibroblasts in the substantia propria. These changes were
proportional to the amount of medication instilled and to
length of drug administration. The reduction of cellular via-
bility and apoptosis of conjunctival epithelial cells follo-
wing the use of antiglaucoma medications have also been
related to exposure time, number of drugs in use and their
concentration, but there is little information available about
the influence of PG analogues(13,21,29-32).
Our study demonstrated that PG analogues induce less
severe changes in the rabbit conjunctival epithelium than
timolol maleate. In the group treated with timolol, there was a
significant increase in conjunctival epithelial thickness and
a marked increase of subepithelial collagen density, a fin-
ding that is consistent with the literature(13,18,21,24,29-30). This
finding may be secondary to epithelial cell edema, or to the
presence of an inflammatory infiltrate, also found in greater
intensity in timolol-treated eyes, and may partially explain
the occurrence of dry eye symptoms in patients using timolol
maleate. Several studies also demonstrated that timolol may
induce a drop in goblet cells and a crystallization pattern
associated with keratoconjunctivitis sicca(17,21,29). Timolol
has the larger decline of all drugs, but no significant differen-
ces were observed.
We observed a rise in goblet cells in the groups treated
with PG analogues, a finding that was previously described
for latanoprost(22-33). However, our study is the first to confirm
that the increase in goblet cells may also be observed with
other PG analogues, such as travoprost and bimatoprost. Al-
though the consequences of an increased goblet cell popu-
lation remain unknown, we hypothesize that this finding may
explain why the long-term use of PG analogues is associated
with less severe dry eye symptoms than those induced by
timolol maleate.
Our study also demonstrated a rise in blood vessels in the
timolol and latanoprost groups. Interestingly, bimatoprost
and travoprost, which were shown to induce conjunctival
hyperemia in glaucomatous patients(4-5), were not found to
increase the number of blood vessels in the rabbit model.
A diffuse inflammatory infiltrate was noted in moderate
intensity in the groups receiving PG analogues and in severe
intensity in the timolol group, which also showed an increa-
sed subepithelial collagen density. The subclinical inflam-
mation associated with the use of latanoprost was reported by
others(14,31), who described inflammatory cells in the conjunc-
tival epithelium and substantia propria, demonstrated by his-
topathological analysis as well as by immunohistochemical
markers (HLA-DR, IL-6, IL-8). Our study suggests that the
inflammatory infiltrate observed with the use of latanoprost is
also found with other PG analogues. The finding of a dense
inflammatory infiltrate in eyes using timolol maleate is in
agreement with previous reports(13,20-21,24,29,34).
It was shown that long-term topical treatment of glauco-
ma induces an increase in collagen deposition(14,35). Mietz
et al.(14) investigated rabbits that used timolol, latanoprost,
or the fixed combination of timolol and latanoprost for 18
months. At the end of the follow-up period, the conjunctiva
showed an increased density of collagen fibers in the subs-
tantia propria of eyes treated with timolol and the fixed com-
bination of timolol and latanoprost, but not in eyes treated
with latanoprost alone. In our study, this finding was confir-
med for timolol maleate and was detected earlier than in other
reports(14,35). An up-regulation of matrix metalloproteinases
may explain why PG analogues did not induce changes in
collagen density. Metalloproteinases are essential to control
tissue remodeling and may influence the scarring process of
filtering blebs after glaucoma surgery(14-15,35-36). Latanoprost-
treated eyes showed an up-regulation of matrix metallo-
proteinases (MMP-3) and their tissue inhibitors (TIMP-2),
leading to reduced extracellular accumulations of amor-
phous material in the conjunctiva.
Several studies suggested that the surgical outcome of
trabeculectomy is less favorable in patients who received
previous topical antiglaucoma therapy(13,19,24,28,37). Broadway
et al.s(19) identified preoperative subclinical conjunctival
inflammation induced by previous topical medication as a
risk factor for failure of trabeculectomy. The reduction of
success rates of glaucoma filtering procedures is probably
due to the activation of fibroblasts from the conjunctiva,
Tenon’s, and episclera, leading to the formation of scar tissue
surrounding the scleral flap(27,37). The presence of an inflam-
matory infiltrate (induced by all antiglaucoma medications,
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but more severe in the timolol group) may induce fibroblast
activation(13,17,29,37). Furthermore, the increased collagen
density detected in the timolol group may already be a con-
sequence of enhanced fibroblast activity.
Clinical, laboratory and experimental studies have sug-
gested that conjunctival morphological changes were
strongly associated with BAK, the most frequently used
preservative in ophthalmic topical medications(16,38-39).
Pisella et al.(40), using impression citology to compare to-
xicity of latanoprost and unpreserved or preserved timolol
maleate, evaluated inflammatory markers and MUC5AC-
related mucin production in the conjunctiva of chronic
users in a case-control ex-vivo study. Only patients treated
for at least one year were included in this study and com-
pared to normal subjects. HLA-DR, ICAM-1 and mucin were
evaluated in a masked manner by flow citometry. For the in
vitro study, a human conjunctiva derived cell-line was trea-
ted with 0.02% BAK-containing latanoprost or timolol, un-
preserved timolol, or 0.02% BAK alone for 15 minutes, and
cell viability and chromatin condensation were evaluated.
These in vitro studies demonstrated that BAK-containing
latanoprost and timolol exhibited higher proinflammatory
and proapoptotic effects on conjunctival cells than
unpreserved timolol. Latanoprost was found to induce
fewer changes than preserved timolol, which is in agree-
ment with our study.
The only study that investigated the effects of the three
available PG analogues on the conjuntiva was reported by
Guenoun et al.(32). The authors performed in-vitro and ex-
vivo experiments using human conjunctiva-derived cell li-
nes to evaluate toxicity and expression of human inflamma-
tory markers induced by PG analogues and BAK. PG analo-
gues did not induce expression of inflammatory markers and
even reduced the expression of ICAM-1 and PECAM-1 in the
solutions with higher concentrations of BAK. The results of
the previously described studies(32,40) suggest a protective
effect of PG analogues against preservative (BAK) toxicity
due to possible antioxidative properties.
Contrary to the literature available, the present investiga-
tion was not able to detect marked conjunctival changes in
the BAK group. This discrepancy may be due to short expo-
sure time to the preservative in our study, to its low concen-
tration in the solution used (0.006% compared to other stu-
dies that used 0.02%), or to the association of BAK and
hypromellose and dextran 70 in artificial tears(41).
In conclusion, although a moderate, diffuse inflammatory
infiltrate was observed in PG-treated eyes, no changes in
conjunctival epithelial thickness or subconjunctival colla-
gen density were observed with these medications, sugges-
ting that these drugs induce fewer changes than timolol ma-
leate in the rabbit conjunctiva. Further studies are needed to
investigate the influence of PG analogues versus other clas-
ses of antiglaucoma medications on the success rates of eyes
undergoing trabeculectomy.
RESUMO
Objetivos: Comparar alterações histológicas induzidas por
medicação anti-glaucomatosa na conjuntiva de coelhos. Mé-
todos: Cinqüenta coelhos da raça Nova Zelândia foram divi-
didos em 5 grupos de 10 animais. Os olhos esquerdos foram
tratados com uma gota diária de bimatoprosta 0,03%, travo-
prosta 0,004%, latanoprosta 0,005%, maleato de timolol
0,5% ou lágrimas artificiais contendo cloreto de benzalcônio
(BAK) por 30 dias. Os olhos direitos serviram como contro-
les. Foram realizadas biópsias conjuntivais límbicas superio-
res no 8º e 30º dias em 5 coelhos de cada grupo. A conjuntiva
foi fixada com formaldeído 10%, seguido por coloração de
HE e PAS. Foi realizada análise quantitativa morfohisto-
métrica para avaliar os seguintes parâmetros: infiltrado infla-
matório, espessura epitelial, número de células calicifor-
mes, diâmetro e número de vasos sanguíneos. Resultados: No
8º e 30º dias de tratamento, todos os grupos, exceto aquele
que recebeu lágrimas artificiais, exibiram infiltrado inflama-
tório difuso, composto por linfócitos e neutrófilos, sendo
mais denso no grupo timolol do que nos grupos dos análogos
de prostaglandinas. No 30º dia, o grupo timolol apresentou
um aumento na densidade de colágeno subepitelial e um au-
mento significativo da espessura epitelial (p=0,0035). A densi-
dade de células caliciformes aumentou significativamente no
8º dia no grupo tratado com travoprosta (p=0,0006), e no 30º
dia nos grupos tratados com bimatoprosta (p=0,0021) e lata-
noprosta (p=0,009). Conclusões: Embora tenha sido observa-
do um infiltrado inflamatório difuso e moderado nos olhos
tratados com análogos de prostaglandinas, não houve altera-
ções na espessura epitelial conjuntival ou densidade colágena
subepitelial com essas medicações, sugerindo que essas drogas
induzem menores alterações que o maleato de timolol na
conjuntiva de coelhos.
Descritores: Prostaglandinas sintéticas; Timolol/uso tera-
pêutico; Conjuntiva; Glaucoma/quimioterapia; Coelhos
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